Cardiac mTOR complex 2 preserves ventricular function in pressure-overload hypertrophy

被引:53
|
作者
Shende, Pankaj [1 ,2 ]
Xu, Lifen [1 ,2 ]
Morandi, Christian [1 ,2 ]
Pentassuglia, Laura [1 ,2 ]
Heim, Philippe [1 ,2 ]
Lebboukh, Sonia [1 ,2 ]
Berthonneche, Corinne [3 ,4 ]
Pedrazzini, Thierry [3 ,4 ]
Kaufmann, Beat A. [1 ,2 ]
Hall, Michael N. [5 ]
Rueegg, Markus A. [5 ]
Brink, Marijke [1 ,2 ]
机构
[1] Univ Basel, Dept Biomed, Hebelstr 20, CH-4031 Basel, Switzerland
[2] Univ Basel Hosp, Hebelstr 20, CH-4031 Basel, Switzerland
[3] Univ Lausanne, Sch Med, Dept Med, Lausanne, Switzerland
[4] Univ Lausanne, Sch Med, Cardiovasc Assessment Facil, Lausanne, Switzerland
[5] Univ Basel, Biozentrum, Hebelstr 20, CH-4031 Basel, Switzerland
基金
瑞士国家科学基金会;
关键词
Heart failure; Hypertrophy; Metabolism; Signal transduction; PROTEIN-KINASE-C; PKC-DELTA; MAMMALIAN TARGET; HEART-FAILURE; MOTIF PHOSPHORYLATION; THERAPEUTIC TARGET; TRANSGENIC MICE; S6; KINASES; IN-VIVO; AKT;
D O I
10.1093/cvr/cvv252
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Aims Mammalian target of rapamycin (mTOR), a central regulator of growth and metabolism, has tissue-specific functions depending on whether it is part of mTOR complex 1 (mTORC1) or mTORC2. We have previously shown that mTORC1 is required for adaptive cardiac hypertrophy and maintenance of function under basal and pressure-overload conditions. In the present study, we aimed to identify functions of mTORC2 in the heart. Methods and Results Using tamoxifen-inducible cardiomyocyte-specific gene deletion, we generated mice deficient for cardiac rapamycin-insensitive companion of mTOR (rictor), an essential and specific component of mTORC2. Under basal conditions, rictor deficiency did not affect cardiac growth and function in young mice and also had no effects in adult mice. However, transverse aortic constriction caused dysfunction in the rictor-deficient hearts, whereas function was maintained in controls after 1 week of pressure overload. Adaptive increases in cardiac weight and cardiomyocyte cross-sectional area, fibrosis, and hypertrophic and metabolic gene expression were not different between the rictor-deficient and control mice. In control mice, maintained function was associated with increased protein levels of rictor, protein kinase C (PKC)beta II, and PKC delta, whereas rictor ablation abolished these increases. Rictor deletion also significantly decreased PKC epsilon at baseline and after pressure overload. Our data suggest that reduced PKC epsilon and the inability to increase PKC beta II and PKC delta abundance are, in accordance with their known function, responsible for decreased contractile performance of the rictor-deficient hearts. Conclusion Our study demonstrates that mTORC2 is implicated in maintaining contractile function of the pressure-overloaded male mouse heart.
引用
收藏
页码:103 / 114
页数:12
相关论文
共 50 条
  • [1] Maintaining Cardiac Fatty Acid Oxidation in Pressure-Overload Hypertrophy Preserves Function and Energetics
    Kolwicz, Stephen C., Jr.
    Olson, David P.
    Marney, Luke
    Garcia-Menendez, Lorena
    Ngoy, Soeun
    Synovec, Robert E.
    Liao, Ronglih
    Tian, Rong
    CIRCULATION, 2011, 124 (21)
  • [2] Inhibition of mTOR reduces chronic pressure-overload cardiac hypertrophy and fibrosis
    Gao, Xiao-Ming
    Wong, Geoffrey
    Wang, Binghui
    Kiriazis, Helen
    Moore, Xiao-Lei
    Su, Yi-Dan
    Dart, Anthony
    Du, Xiao-Jun
    JOURNAL OF HYPERTENSION, 2006, 24 (08) : 1663 - 1670
  • [3] DETERMINANTS OF VENTRICULAR-FUNCTION IN PRESSURE-OVERLOAD HYPERTROPHY IN MAN
    GUNTHER, S
    GROSSMAN, W
    CIRCULATION, 1979, 59 (04) : 679 - 688
  • [4] Calcineurin expression, activation, and function in cardiac pressure-overload hypertrophy
    Lim, HW
    De Windt, LJ
    Steinberg, L
    Taigen, T
    Witt, SA
    Kimball, TR
    Molkentin, JD
    CIRCULATION, 2000, 101 (20) : 2431 - 2437
  • [5] Cytoskeletal mechanics in pressure-overload cardiac hypertrophy
    Tagawa, H
    Wang, N
    Narishige, T
    Ingber, DE
    Zile, MR
    Cooper, G
    CIRCULATION RESEARCH, 1997, 80 (02) : 281 - 289
  • [6] Signalling pathways in pressure-overload cardiac hypertrophy
    Peivandi, A. A.
    Loeffelholz, K.
    Vahl, C. F.
    ZEITSCHRIFT FUR HERZ THORAX UND GEFASSCHIRURGIE, 2009, 23 (01): : 9 - 16
  • [7] Pharmacological modulation of pressure-overload cardiac hypertrophy - Changes in ventricular function, extracellular matrix, and gene expression
    Wong, K
    Boheler, KR
    Petrou, M
    Yacoub, MH
    CIRCULATION, 1997, 96 (07) : 2239 - 2246
  • [8] STRUCTURE AND FUNCTION OF CANINE CARDIAC MYOSIN DURING PRESSURE-OVERLOAD CARDIAC-HYPERTROPHY
    SIEMANKOWSKI, RF
    DREIZEN, P
    BULLETIN OF THE NEW YORK ACADEMY OF MEDICINE, 1979, 55 (04) : 429 - 430
  • [9] STRUCTURE AND FUNCTION OF CANINE CARDIAC MYOSIN DURING PRESSURE-OVERLOAD CARDIAC-HYPERTROPHY
    SIEMANKOWSKI, RF
    DREIZEN, P
    ACTA PROTOZOOLOGICA, 1979, 18 (01) : 199 - 199
  • [10] Melatonin Blunts Pressure-overload Left Ventricular Hypertrophy and Improves Cardiac Performance in Pathologic and PPhysiologic Cardiac Hypertrophy
    Offerhaus, Joost
    Lee, Dong
    Bedja, Djahida
    Cingolani, Oscar
    CIRCULATION, 2015, 132